FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q44616783> ?p ?o ?g. }

• Q44616783 description "2003 nî lūn-bûn" @default.
• Q44616783 description "2003年の論文" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年学术文章" @default.
• Q44616783 description "2003年學術文章" @default.
• Q44616783 description "2003年學術文章" @default.
• Q44616783 description "2003年學術文章" @default.
• Q44616783 description "2003年學術文章" @default.
• Q44616783 description "2003年學術文章" @default.
• Q44616783 description "2003년 논문" @default.
• Q44616783 description "article científic" @default.
• Q44616783 description "article scientific" @default.
• Q44616783 description "article scientifique" @default.
• Q44616783 description "articol științific" @default.
• Q44616783 description "articolo scientifico" @default.
• Q44616783 description "artigo científico" @default.
• Q44616783 description "artigo científico" @default.
• Q44616783 description "artigo científico" @default.
• Q44616783 description "artikel ilmiah" @default.
• Q44616783 description "artikull shkencor" @default.
• Q44616783 description "artikulong pang-agham" @default.
• Q44616783 description "artykuł naukowy" @default.
• Q44616783 description "artículo científico publicado en 2003" @default.
• Q44616783 description "artículu científicu" @default.
• Q44616783 description "bilimsel makale" @default.
• Q44616783 description "bài báo khoa học" @default.
• Q44616783 description "naučni članak" @default.
• Q44616783 description "scienca artikolo" @default.
• Q44616783 description "scientific article published on 14 October 2003" @default.
• Q44616783 description "scientific article published on 14 October 2003" @default.
• Q44616783 description "scientific article published on 14 October 2003" @default.
• Q44616783 description "teaduslik artikkel" @default.
• Q44616783 description "tieteellinen artikkeli" @default.
• Q44616783 description "tudományos cikk" @default.
• Q44616783 description "vedecký článok" @default.
• Q44616783 description "vetenskaplig artikel" @default.
• Q44616783 description "videnskabelig artikel" @default.
• Q44616783 description "vitenskapelig artikkel" @default.
• Q44616783 description "vitskapeleg artikkel" @default.
• Q44616783 description "vědecký článek" @default.
• Q44616783 description "wetenschappelijk artikel" @default.
• Q44616783 description "wissenschaftlicher Artikel" @default.
• Q44616783 description "επιστημονικό άρθρο" @default.
• Q44616783 description "мақолаи илмӣ" @default.
• Q44616783 description "наукова стаття, опублікована в жовтні 2003" @default.
• Q44616783 description "научна статия" @default.
• Q44616783 description "научная статья" @default.
• Q44616783 description "научни чланак" @default.
• Q44616783 description "научни чланак" @default.
• Q44616783 description "מאמר מדעי" @default.
• Q44616783 description "مقالة علمية نشرت في 14 أكتوبر 2003" @default.
• Q44616783 description "১৪ অক্টোবর ২০০৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
• Q44616783 description "บทความทางวิทยาศาสตร์" @default.
• Q44616783 description "სამეცნიერო სტატია" @default.
• Q44616783 name "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 name "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 type Item @default.
• Q44616783 label "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 label "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 prefLabel "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 prefLabel "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study." @default.
• Q44616783 P1433 Q44616783-514BC96A-C85F-4EFB-BEBF-E3FA3BC98FF7 @default.
• Q44616783 P1476 Q44616783-27E75D35-11DC-42A4-822C-695D73F0EADD @default.
• Q44616783 P2093 Q44616783-2D715399-FE73-493E-A6A0-59B8A4014B87 @default.
• Q44616783 P2093 Q44616783-3A4D9195-37F0-4F29-A700-6E4A06F36A03 @default.
• Q44616783 P2093 Q44616783-3FAD5B37-FE5F-4E2F-A93B-67C4ADC614CE @default.
• Q44616783 P2093 Q44616783-4209E6BA-4B3A-4AAB-B19A-E87496D46A36 @default.
• Q44616783 P2093 Q44616783-4A2218FB-914E-49A4-97D7-3F82D3F744DD @default.
• Q44616783 P2093 Q44616783-52BC0DE7-7A58-4216-90AA-C6BFF4FFBEDA @default.
• Q44616783 P2093 Q44616783-52DAA7FF-D95C-4D67-B1B5-5B29B54C23FA @default.
• Q44616783 P2093 Q44616783-53997AC0-821E-4EF5-B8C7-2CE71E0A6344 @default.
• Q44616783 P2093 Q44616783-557E3A32-DD11-45E4-9E27-B75AD0B9761E @default.
• Q44616783 P2093 Q44616783-5835C5C7-0D44-482D-909E-5AA9B46AFF61 @default.
• Q44616783 P2093 Q44616783-968B2D29-4D7B-4545-8F20-DAB459B20EA8 @default.
• Q44616783 P2093 Q44616783-9ACCC136-EF20-4BEB-8DFB-493050E15438 @default.
• Q44616783 P2093 Q44616783-ACD93FAD-799D-410E-BA24-9124C4CECE5B @default.
• Q44616783 P2093 Q44616783-B3567F0A-2B95-426B-88AD-F6BB83B0B131 @default.
• Q44616783 P2093 Q44616783-D712DD83-E950-4722-9B72-DA7219B4C3E6 @default.
• Q44616783 P2888 Q44616783-E1365F39-6252-4649-8046-3EFA9F3751A1 @default.
• Q44616783 P304 Q44616783-5AB02FAB-8CAC-4D20-B29C-EB6E5D79BBB3 @default.
• Q44616783 P31 Q44616783-C75F0F73-5439-4C36-B41F-16BE1F80970E @default.
• Q44616783 P356 Q44616783-76EB881A-49CD-4C3E-8384-C6DD200A52CD @default.
• Q44616783 P433 Q44616783-0BABFD1D-E470-4E63-A1BE-D697AA553D36 @default.
• Q44616783 P478 Q44616783-76FAE7CA-63B7-4BD3-ABB6-37F54E8B48D2 @default.
• Q44616783 P50 Q44616783-369B2A44-B29E-4862-89B0-3864CAFC48B9 @default.
• Q44616783 P577 Q44616783-18609882-7AFA-4A79-8247-92A8FF0FCD6B @default.
• Q44616783 P698 Q44616783-E829DFC2-3862-4CAA-9050-30CF2C1F1423 @default.
• Q44616783 P921 Q44616783-64CB15DE-4232-44DF-AD87-7B4E884C8664 @default.
• Q44616783 P921 Q44616783-73B396D0-5E4F-4738-9F9F-B515679F8959 @default.
• Q44616783 P921 Q44616783-A45D0950-C7B7-4A2C-962F-D41073674BEE @default.
• Q44616783 P356 S00280-003-0690-0 @default.
• Q44616783 P698 14557896 @default.
• Q44616783 P1433 Q326137 @default.
• Q44616783 P1476 "Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study" @default.
• Q44616783 P2093 "Adolfo Frau" @default.
• Q44616783 P2093 "Amparo Oltra" @default.

• next